Oncology Department

Founded in 1995, the Department of Breast Oncology, a clinical research department focused on the diagnosis of breast cancer with deep roots in hereditary and evolving research, has been dedicated for many years to the standardization of lung cancer, personalized internal medicine and multidisciplinary integrated therapy and related transformational research. Always insist on closely combining the latest international clinical trials and transformative research advances with clinical practice, developing and optimizing regulated treatment programs for late-stage lung cancer, especially in the last decade of active exploration, development and development of multidisciplinary integrated diagnostics for lung cancer, immunotherapy and immunotherapy, and increasing international and domestic influence. A mature, stable academic direction: a branch of breast cancer that focuses on the cutting edge of lung cancer research, with major research directions for predicting chemotherapy in tumor tissue and peripheral blood, molecular orientation and immunotherapy therapies, and predictive molecular signaling, laying a solid foundation for individual treatment. International early testing of EGFR gene mutations in the external circulatory blood, innovative research into the relationship between the tumour and its development and therapeutic effects, exploration of the external circulatory prediction model for lung cancer immunotherapy and drug resistance mechanisms.